ABVX
Abivax SA American Depositary SharesKey Statistics
About Abivax SA American Depositary Shares
Abivax SA is a clinical-stage biotechnology company dedicated to developing groundbreaking immunotherapies for chronic inflammatory diseases and viral infections, leveraging its lead candidate ABX464, currently undergoing clinical trials for ulcerative colitis and other indications. The firm employs a unique combination of antibody-mediated therapies and proprietary compounds to address significant unmet medical needs, positioning itself favorably within the healthcare landscape. With a promising pipeline and a skilled scientific team committed to innovation, Abivax represents a compelling investment opportunity for institutional stakeholders looking to capitalize on advancements in the immunotherapy sector.
Fundamentals
| Revenue (TTM) | $4.57M |
| Gross Profit (TTM) | $4.57M |
| EBITDA | $-244.98M |
| Operating Margin | -3743.00% |
| Return on Equity | -135.60% |
| Return on Assets | -39.00% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $6.79 |
| Price-to-Book | 16.35 |
| Price-to-Sales (TTM) | 1906.29 |
| EV/Revenue | 157.63 |
| EV/EBITDA | -12.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -55.40% |
| Shares Outstanding | $79.29M |
| Float | $64.14M |
| % Insiders | 0.00% |
| % Institutions | 78.90% |
Historical Volatility
Volatility is currently contracting